|
gptkbp:instance_of
|
gptkb:depression
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Pristiq
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:class
|
serotonin-norepinephrine reuptake inhibitor (SNRI)
|
|
gptkbp:clinical_trial
|
NCT00132100
NCT00132113
NCT00132126
NCT00132139
NCT00132152
|
|
gptkbp:contraindication
|
MAO inhibitors
severe renal impairment
|
|
gptkbp:discontinuation_symptoms
|
may occur
|
|
gptkbp:dosage_form
|
gptkb:tablet
100 mg once daily
50 mg once daily
|
|
gptkbp:duration
|
at least 6 weeks
|
|
gptkbp:effective_date
|
2008-02-29
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:healthcare
|
gptkb:2008
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pristiq
|
|
gptkbp:ingredients
|
gptkb:desvenlafaxine
|
|
gptkbp:interacts_with
|
gptkb:beer
NSAIDs
anticoagulants
other antidepressants
|
|
gptkbp:lifespan
|
11 hours
|
|
gptkbp:long_term_use
|
possible side effects
|
|
gptkbp:manufacturer
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patient_population
|
consult healthcare provider
|
|
gptkbp:previous_name
|
gptkb:desvenlafaxine
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety
|
monitor for suicidal thoughts
|
|
gptkbp:side_effect
|
dizziness
nausea
insomnia
constipation
dry mouth
sweating
sexual dysfunction
|
|
gptkbp:strength
|
100 mg
50 mg
|
|
gptkbp:suitable_for
|
pregnant women
children under 18
breastfeeding women
|
|
gptkbp:symptoms
|
possible
|
|
gptkbp:type_of_care
|
important
|
|
gptkbp:used_for
|
major depressive disorder
|
|
gptkbp:bfsParent
|
gptkb:Desvenlafaxine
|
|
gptkbp:bfsLayer
|
6
|